[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 209 0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 65, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 943020, "exercisedValue": 0, "unexercisedValue": 137562}, {"maxAge": 1, "name": "Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.", "age": 78, "title": "Founder & Independent Director", "yearBorn": 1947, "fiscalYear": 2024, "totalPay": 48125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 38, "title": "Chief Scientific Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 648600, "exercisedValue": 0, "unexercisedValue": 54705}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 59, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 721087, "exercisedValue": 0, "unexercisedValue": 86025}, {"maxAge": 1, "name": "Dr. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preetam  Shah M.B.A., Ph.D.", "age": 53, "title": "Chief Strategy & Financial Officer and Treasurer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marc J. Wolfgang M.S.", "title": "Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.01, "open": 8.01, "dayLow": 7.88, "dayHigh": 8.19, "regularMarketPreviousClose": 8.01, "regularMarketOpen": 8.01, "regularMarketDayLow": 7.88, "regularMarketDayHigh": 8.19, "payoutRatio": 0.0, "beta": 2.154, "forwardPE": -5.38206, "volume": 98363, "regularMarketVolume": 98363, "averageVolume": 99430, "averageVolume10days": 88950, "averageDailyVolume10Day": 88950, "bid": 8.0, "ask": 8.19, "bidSize": 1, "askSize": 1, "marketCap": 139795088, "fiftyTwoWeekLow": 4.6, "fiftyTwoWeekHigh": 12.62, "allTimeHigh": 263.0, "allTimeLow": 2.96, "fiftyDayAverage": 8.2791, "twoHundredDayAverage": 8.5222, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 135994000, "profitMargins": 0.0, "floatShares": 11791297, "sharesOutstanding": 17258652, "sharesShort": 1062869, "sharesShortPriorMonth": 1119019, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0616, "heldPercentInsiders": 0.36771, "heldPercentInstitutions": 0.11934, "shortRatio": 10.21, "shortPercentOfFloat": 0.0917, "impliedSharesOutstanding": 17258652, "bookValue": 0.221, "priceToBook": 36.651585, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -45857000, "trailingEps": -3.11, "forwardEps": -1.505, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -3.23, "52WeekChange": -0.009888768, "SandP52WeekChange": 0.14987159, "quoteType": "EQUITY", "currentPrice": 8.1, "targetHighPrice": 18.0, "targetLowPrice": 13.0, "targetMeanPrice": 15.5, "targetMedianPrice": 15.5, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 20611000, "totalCashPerShare": 1.179, "ebitda": -42108000, "totalDebt": 15057000, "quickRatio": 3.164, "currentRatio": 3.295, "debtToEquity": 394.575, "returnOnAssets": -0.79396003, "freeCashflow": -22453250, "operatingCashflow": -38899000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ELTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketTime": 1769202021, "regularMarketTime": 1769202001, "exchange": "NCM", "messageBoardId": "finmb_214936128", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.1236, "regularMarketPrice": 8.1, "priceEpsCurrentYear": -3.233533, "fiftyDayAverageChange": -0.17910004, "fiftyDayAverageChangePercent": -0.021632789, "twoHundredDayAverageChange": -0.42219925, "twoHundredDayAverageChangePercent": -0.049541112, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Angion Biomedica Corp.", "nameChangeDate": "2026-01-23", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "corporateActions": [], "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612535400000, "postMarketChangePercent": 0.0, "postMarketPrice": 8.1, "postMarketChange": 0.0, "regularMarketChange": 0.0900002, "regularMarketDayRange": "7.88 - 8.19", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 99430, "fiftyTwoWeekLowChange": 3.5000005, "fiftyTwoWeekLowChangePercent": 0.7608697, "fiftyTwoWeekRange": "4.6 - 12.62", "fiftyTwoWeekHighChange": -4.5199995, "fiftyTwoWeekHighChangePercent": -0.3581616, "fiftyTwoWeekChangePercent": -0.9888768, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755288000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.11, "epsForward": -1.505, "epsCurrentYear": -2.505, "displayName": "Elicio Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-24"}]